Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia (LLC2007SA)
Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO
RATIONALE: Classical chemotherapy does not cure advanced chronic lymphocytic leukemia (CLL) despite new drugs. Rituximab is a monoclonal antibody directed against CD20 surface antigen on B lymphocytes and leads to apoptosis of CD20 positive B lymphocytes. The highest response rate yet published in the treatment of first-line CLL has been obtained by the association of fludarabine, cyclophosphamide and rituximab (FCR). Now, the question is whether this response can be improved, as some trials showed that eradication of minimal residual disease (MRD) in CLL is associated with a longer treatment-free and overall survival. Maintenance therapy using rituximab has been recently approved as a means of prolonging remission in patients with indolent non Hodgkin's lymphoma. Maintenance therapy with rituximab could be of interest in treatment of MRD in CLL and prolonging remission and survival times.
PURPOSE: The overall purpose of the study is to determine the value of immunotherapy maintenance with single agent rituximab in comparison with no further treatment (observation ) for previously untreated chronic lymphocytic leukaemia in elderly (>65 years) patients who respond to induction immunochemotherapy with FCR.
研究概览
详细说明
OBJECTIVES:
Primary
- To demonstrate superiority, in terms of 3-year progression-free survival (PFS), of rituximab maintenance over observation in patients who are in complete or partial response (CR or PR) after induction therapy comprising fludarabine, cyclophosphamide, and rituximab.
Secondary
- To determine event-free survival, disease-free survival, overall survival, and time to next treatment, all from time of randomization.
- To determine overall response rate (CR and PR) according to NCI and iwCLL criteria
- To assess the rate of phenotypic response (minimal residual disease).
- To assess duration of phenotypic and NCI and iwCLL clinical responses.
- To determine response rates and time-related parameters in biological subgroups.
- To determine rates of treatment-related adverse events.
- To evaluate CD4/CD8 counts, immunoglobulin levels, and incidence of Coombs-positive hemolytic anemia.
- To study pharmacokinetics of rituximab during induction and maintenance.
- To evaluate the prognostic impact of the immunoglobulin FcγRIIIA genotype.
- To assess quality of life.
- To study pharmacoeconomics.
OUTLINE: This is a multicenter study. Randomization is stratified according to response to induction therapy (complete response [CR] vs partial response [PR]), IGHV mutational status, and 11q deletion.
Patients receive rituximab IV on days 1 and 14 of courses 1-2 and on day 1 of courses 3 and 4. Patients also receive oral fludarabine and oral cyclophosphamide once daily on days 2-4 of course 1 and on days 1-3 of courses 2-4. Courses are administered every 28 days. Patients achieving CR or PR are randomized 1:1 to maintenance arm or observation arm.
- Arm A: Patients receive rituximab IV every 2 months in the absence of disease progression or unacceptable toxicity for a maximum duration of 24 months (12 infusions).
- Arm B: Patients undergo observation only.
After completion of study therapy, patients are followed every 3 months for 1 year and then every 6 months for 2 years.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
TOURS Cedex、法国、37044
- French Innovative Leukemia Organization
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria
- B-CLL
- Matutes score 4 or 5
- Binet stages B or C
- Age > 65 years old
- No previous treatment of CLL by chemotherapy, radiotherapy or immunotherapy, except glucocorticoids < 1 month
- Patient's written informed consent
- Life expectancy > 6 months
Exclusion criteria
- Binet stage A
- ECOG performance status 2 or more
- Presence of a 17p deletion by FISH (> 10% positive cores)
- Clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as judged by the treating physician
- Patients with a history of another malignancy in complete remission less than 5 years, except basal cell skin cancer or tumor treated curatively by surgery
- Concomitant disease requiring prolonged use of corticosteroids (> 1 month)
- Any severe co-morbidities such as NYHA Class III or IV heart failure, myocardial infarction within 6 months, unstable angina, ventricular tachyarrhythmias requiring ongoing treatment, severe uncontrolled myocardiopathy, uncontrolled hypertension, severe chronic obstructive pulmonary disease with hypoxemia, or uncontrolled diabetes mellitus.
- CIRS (Cumulative Illness rating Scale) > 6
- Known hypersensitivity to murine proteins or to any of the study drugs or to their components
- Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma) or prolymphocytic leukemia
- Active bacterial, viral or fungal infection
- Seropositivity HIV, hepatitis C or hepatitis B (unless clearly due to vaccination)
- Total bilirubin, alkaline phosphatases and aminotransferases > 2 x ULN
- Creatinine clearance < 60 ml/min calculated according to the formula of Cockcroft and Gault
- Any coexisting medical or psychological condition that would preclude participation to the required study procedures
- Patient with mental deficiency preventing proper understanding of the requirements of treatment
Inclusion criteria at randomization
- Patients having received the full induction phase with 4 FC and 6 rituximab courses (with/without dose adjustments as per protocol)
- Complete or partial response according to NCI and iwCLL criteria at the end of induction phase
- Recovery from FCR toxicities
- Patient willingness to continue on protocol
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预：Observation
Observation every 8 weeks during 2 years
|
|
|
实验性的：rituximab arm
rituximab :500 mg/m² every 8 weeks during 2 years
|
rituximab :500 mg/m² every 8 weeks during 2 years
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival
大体时间：randomization until disease progression or death
|
Progression-free survival is defined as the time from randomization to the first occurrence of disease progression, relapse or death from any cause; using iwCLL criteria
|
randomization until disease progression or death
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event-free survival
大体时间：randomization until disease progression, death, new CLL treatment, and secondary cancer
|
Event-free survival is defined as the time from randomization to the occurrence of one of the following events, whichever occurs first: disease progression or relapse, death from any cause, initiation of any new anti-CLL therapy, and secondary malignancy
|
randomization until disease progression, death, new CLL treatment, and secondary cancer
|
|
Disease-free survival
大体时间：first documented CR until relapse
|
Disease-free survival is defined as the time from first documented CR to relapse
|
first documented CR until relapse
|
|
Overall survival
大体时间：randomization until death
|
Overall survival is defined as the time from randomization to death from any cause
|
randomization until death
|
|
Time to next treatment
大体时间：randomization until new CLL treatment
|
Time to next treatment is defined as the time from randomization to initiation of a new CLL-related treatment
|
randomization until new CLL treatment
|
|
Overall response rate
大体时间：baseline up to approximately 66 months
|
Overall response rate is defined by the percentage of participants with an overall response; CR or PR according to NCI criteria and CR, CRi or PR according to iwCLL
|
baseline up to approximately 66 months
|
|
Phenotypic response rate
大体时间：randomization up to approximately 60 months
|
Phenotypic response rate is defined by the percentage of participants with minimal residual disease negativity as measured by six-colour flow cytometry with a sensitivity of 0.7 x 10-5.
MRD is considered as undetectable when the positivity criteria, defined as the presence of at least 20 CLL cells, is not reached
|
randomization up to approximately 60 months
|
|
Rates of treatment-related adverse events
大体时间：safety since baseline
|
Rate of treatment-related adverse events (plus adverse events of particular interest) is defined as the percentage of participants with adverse events assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and version 2.0.
for hematological toxicity
|
safety since baseline
|
|
Pharmacokinetics of rituximab
大体时间：baseline up to approximately 36 months
|
Pharmacokinetics of rituximab during induction and rituximab maintenance
|
baseline up to approximately 36 months
|
|
Quality of life
大体时间：baseline up to approximately 30 months
|
Change from baseline in EORTC Quality of Life Questionnaire Core 30
|
baseline up to approximately 30 months
|
合作者和调查者
调查人员
- 首席研究员：Caroline Dartigeas, MD、Hématologie et Thérapie Cellulaire Hôpital Bretonneau CHU Tours FRANCE
- 首席研究员：Eric VAN DEN NESTE, MD PhD、Département d'hématologie Cliniques Universitaires Saint Luc BRUSSELS BELGIUM
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CDR0000589684
- CHRUT-LLC-2007-SA (其他标识符：CHU Tours)
- CHRUT-PHRN05-CD (其他标识符：CHU Tours)
- INCA-RECF0497 (其他标识符：INCA)
- 2007-001015-28 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.